大凌集團(00211.HK):11.76億份認股權證將於11月19日主板上市
格隆匯11月15日丨大凌集團(00211.HK)公佈,公司已向聯交所上市委員會申請批准此前所述將予發行的認股權證,以及認股權證所附之認購權獲行使時將予發行的任何股份上市及買賣。預期認股權證將於2019年11月19日(星期二)上午九時正起在聯交所主板開始買賣。認股權證將以每手5萬份為買賣單位進行買賣。認股權證的證券代號為1435。
公司將因發行紅利認股權證(以認股權證證書代表)而向股東發行合共11.76億份認股權證,並以記名方式賦予有關持有人權利,可於2019年11月18日至20220年11月17日止期間,隨時按初步行使價每股股份0.01港元(可予調整),以現金認購11.76億股新股份。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.